Leukemia inhibitory factor (LIF) in acute graft-versus-host disease: A hypothesis-generating review
Clinical Immunology · 2026-01 · 282 · 110640
DOI: 10.1016/j.clim.2025.110640 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Immunology, 2026-01. Verfasst von Ahmad Meshkin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Hauptthemen laut MEDLINE: Graft vs Host Disease, Leukemia Inhibitory Factor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Shahid Sadoughi University of Medical Sciences and Health Services.
Abstract (Originalsprache)
Leukemia inhibitory factor (LIF) is a multifunctional cytokine of the IL-6 family, originally identified in murine leukemia cells. Graft-versus-host disease (GvHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), primarily affecting the intestine, liver, and skin. Preclinical studies suggest that LIF may protect against GvHD by preserving intestinal stem cells, reducing radiation- and cytokine-induced tissue injury, decreasing donor T-cell infiltration, and suppressing inflammatory cytokine production; importantly, it appears to preserve graft-versus-leukemia (GVL) activity. This review summarizes current knowledge on the immunopathogenesis of acute GvHD (aGvHD) and examines the emerging but limited evidence on the immunomodulatory role of LIF. We propose a hypothesis-driven framework for its potential therapeutic application. We highlight the immunomodulatory properties of LIF, including its roles in suppressing proinflammatory responses and promoting regulatory mechanisms. LIF's ability to reduce GvHD severity without compromising GVL highlights its potential as a therapeutic agent. Given the limited but promising data, further research is warranted to evaluate LIF's clinical applicability and safety in transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
- Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Electronic address: fatemezare91@gmail.com.
- Department of medical laboratory sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
- Department of medical laboratory sciences, School of Paramedicine,Gerash University of Medical Sciences, Gerash, Iran.
Förderung
- Shahid Sadoughi University of Medical Sciences and Health Services
Zitieren
APA
Meshkin, A., Zare, F., Abbasi, M. E., Montazeri, M. S., Badiee, F., & Khodaei, M. M. (2026). Leukemia inhibitory factor (LIF) in acute graft-versus-host disease: A hypothesis-generating review. Clinical Immunology, 282, 110640. https://doi.org/10.1016/j.clim.2025.110640
Vancouver
Meshkin A, Zare F, Abbasi ME, Montazeri MS, Badiee F, Khodaei MM. Leukemia inhibitory factor (LIF) in acute graft-versus-host disease: A hypothesis-generating review. Clinical Immunology. 2026;282:110640. doi:10.1016/j.clim.2025.110640
BibTeX
@article{Meshkin2026,
author = {Meshkin, Ahmad and Zare, Fateme and Abbasi, Mohammad Erfan and Montazeri, Maryam Sadat and Badiee, Fatemeh and Khodaei, Mohammad Masoud},
title = {Leukemia inhibitory factor (LIF) in acute graft-versus-host disease: A hypothesis-generating review},
journal = {Clinical Immunology},
year = {2026},
volume = {282},
pages = {110640},
doi = {10.1016/j.clim.2025.110640}
}
EUVIMED